The risks and benefits of 5α-reductase inhibitors for prostate-cancer prevention

New England Journal of Medicine

Volumn 365, Issue 2, 2011, Pages 97-99

  Theoret, Marc R ^a   Ning, Yang Min ^a   Zhang, Jenny J ^a   Justice, Robert ^a   Keegan, Patricia ^a   Pazdur, Richard ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DUTASTERIDE; FINASTERIDE; PLACEBO; STEROID 5ALPHA REDUCTASE INHIBITOR;

CANCER GRADING; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; DRUG INDICATION; GLEASON SCORE; HUMAN; MORBIDITY; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; RISK BENEFIT ANALYSIS; RISK REDUCTION; SHORT SURVEY;

EID: 79960210525     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMp1106783     Document Type: Short Survey

References (5)

1. Walsh PC. Chemoprevention of prostate cancer. N Engl J Med 2010;362:1237-8.
2. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:215-24. (Pubitemid 36859473)
3. Andriole GL, Bostwick DG, Brawley OW, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010;362:1192-202.
4. Kramer BS, Hagerty KL, Justman S, et al. Use of 5-α-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 clinical practice guideline. J Clin Oncol 2009;27:1502-16.
5. Food and Drug Administration. Briefing information and slides presented at the December 1, 2010, meeting of the Oncologic Drugs Advisory Committee. (http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ OncologicDrugs AdvisoryCommittee/ucm195226.htm.)